529 related articles for article (PubMed ID: 15695591)
1. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
Komarova SV; Pereverzev A; Shum JW; Sims SM; Dixon SJ
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2643-8. PubMed ID: 15695591
[TBL] [Abstract][Full Text] [Related]
2. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells.
Hirotani H; Tuohy NA; Woo JT; Stern PH; Clipstone NA
J Biol Chem; 2004 Apr; 279(14):13984-92. PubMed ID: 14722106
[TBL] [Abstract][Full Text] [Related]
5. Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway.
Pereverzev A; Komarova SV; Korcok J; Armstrong S; Tremblay GB; Dixon SJ; Sims SM
Bone; 2008 Jan; 42(1):150-61. PubMed ID: 17964236
[TBL] [Abstract][Full Text] [Related]
6. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts.
Korcok J; Raimundo LN; Ke HZ; Sims SM; Dixon SJ
J Bone Miner Res; 2004 Apr; 19(4):642-51. PubMed ID: 15005852
[TBL] [Abstract][Full Text] [Related]
7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
9. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
10. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
12. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
Takayanagi H; Kim S; Koga T; Nishina H; Isshiki M; Yoshida H; Saiura A; Isobe M; Yokochi T; Inoue J; Wagner EF; Mak TW; Kodama T; Taniguchi T
Dev Cell; 2002 Dec; 3(6):889-901. PubMed ID: 12479813
[TBL] [Abstract][Full Text] [Related]
13. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
[TBL] [Abstract][Full Text] [Related]
14. Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts.
Xu J; Wang C; Han R; Pavlos N; Phan T; Steer JH; Bakker AJ; Joyce DA; Zheng MH
J Cell Physiol; 2005 Feb; 202(2):554-62. PubMed ID: 15389575
[TBL] [Abstract][Full Text] [Related]
15. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
16. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
17. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
[TBL] [Abstract][Full Text] [Related]
18. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
[TBL] [Abstract][Full Text] [Related]
19. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca
Zeng X; Zhang Y; Wang S; Wang K; Tao L; Zou M; Chen N; Xu J; Liu S; Li X
Biochem Pharmacol; 2017 Jan; 124():57-68. PubMed ID: 27789216
[TBL] [Abstract][Full Text] [Related]
20. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
